Cambridge liquid biopsy and tumour profiling study for patients on experimental pilot study of immune‐oncology drugs using MEDI4736 (durvalumab).

As part of the Experimental Medicine Training Initiative applications are invited for a prestigious fully-funded, clinical research associate-PhD Studentship at the University of Cambridge.

This innovative new initiative is a partnership between the University of Cambridge, Cambridge Biomedical Research Centre and Pharmaceutical Companies. The Studentship is available from 1st October 2017 and provides an unrivalled opportunity to undertake high quality clinical research in the area of cardiovascular physiology/pharmacology, in collaboration with MedImmune. It will appeal to clinical trainees from Medical Oncology.

This project is a unique opportunity to join a collaboration between the Division of Experimental Medicine and Immunotherapeutics at the University of Cambridge, and the Department of Oncology with Astra Zeneca/ MedImmune. The remit is to study the immune phenotype of oesophageal cancer and explore therapeutic effects of personalised, immune checkpoint blockade, with anti PD-L1 therapy both in existing human samples and pre-clinical models. A parallel human, experimental medicine study of durvalumab (MEDI4736) has been developed. The project will explore relationships between tumour genomics, molecular subtype, immune phenotype and disease response.